The impact of low-dose busulfan on clonal dynamics in nonhuman primates

Ken Kuramoto, Dean Follman, Peiman Hematti, Stephanie Sellers, Mikko O. Laukkanen, Ruth Seggewiss, Mark E. Metzger, Allen Krouse, Robert E. Donahue, Christof Von Kalle, Cynthia E. Dunbar

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

An understanding of the number and contribution of individual pluripotent hematopoietic stem cells (HSCs) to the formation of blood lineages has important clinical implications for gene therapy and stem cell transplantation. We have been able to efficiently mark rhesus macaque long-term repopulating stem and progenitor cells with retroviral vectors, and track their in vivo contributions to hematopoiesis using the linear amplification mediated-polymerase chain reaction (LAM-PCR) technique of insertion site analysis. We assessed the impact of busulfan on contributions of individual retrovirally marked clones to hematopoiesis. There were 2 macaques that received transplants of retrovirally transduced CD34+ cells 2 years previously that were then treated with 4 mg/kg busulfan. Despite only transient and mild suppression of peripheral blood counts, the numbers of individual stem/progenitor clones contributing to granulocyte production decreased dramatically, by 80% in the first monkey and by 60% in the second monkey. A similar impact was seen on clones contributing to T cells. The clone numbers recovered gradually back toward baseline by 5 months following busulfan in the first monkey and by 3 months in the second monkey, and have remained stable for more than one year in both animals. Tracking of individual clones with insertionsite-specific primers suggested that clones contributing to hematopoiesis prior to busulfan accounted for the majority of this recovery, but that some previously undetected clones began to contribute during this recovery phase. These results indicate that even low-dose busulfan significantly affects stem and progenitor cell dynamics. The clonal diversity of hematopoiesis was significantly decreased after even a single, clinically well-tolerated dose of busulfan, with slow but almost complete recovery over the next several months, suggesting that true long-term repopulating stem cells were not permanently deleted. However, the prolonged period of suppression of many clones suggests that transplanted HSCs may have a marked competitive advantage if they can engraft and proliferate during this time period, and supports the use of this agent in nonmyeloablative regimens.

Original languageEnglish
Pages (from-to)1273-1280
Number of pages8
JournalBlood
Volume104
Issue number5
DOIs
Publication statusPublished - Sep 1 2004

Fingerprint

Busulfan
Primates
Clone Cells
Stem cells
Hematopoiesis
Stem Cells
Haplorhini
Recovery
Blood
Hematopoietic Stem Cells
Gene therapy
Transplants
T-cells
Polymerase chain reaction
Pluripotent Stem Cells
Amplification
Macaca
Animals
Stem Cell Transplantation
Macaca mulatta

ASJC Scopus subject areas

  • Hematology

Cite this

Kuramoto, K., Follman, D., Hematti, P., Sellers, S., Laukkanen, M. O., Seggewiss, R., ... Dunbar, C. E. (2004). The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood, 104(5), 1273-1280. https://doi.org/10.1182/blood-2003-08-2935

The impact of low-dose busulfan on clonal dynamics in nonhuman primates. / Kuramoto, Ken; Follman, Dean; Hematti, Peiman; Sellers, Stephanie; Laukkanen, Mikko O.; Seggewiss, Ruth; Metzger, Mark E.; Krouse, Allen; Donahue, Robert E.; Von Kalle, Christof; Dunbar, Cynthia E.

In: Blood, Vol. 104, No. 5, 01.09.2004, p. 1273-1280.

Research output: Contribution to journalArticle

Kuramoto, K, Follman, D, Hematti, P, Sellers, S, Laukkanen, MO, Seggewiss, R, Metzger, ME, Krouse, A, Donahue, RE, Von Kalle, C & Dunbar, CE 2004, 'The impact of low-dose busulfan on clonal dynamics in nonhuman primates', Blood, vol. 104, no. 5, pp. 1273-1280. https://doi.org/10.1182/blood-2003-08-2935
Kuramoto K, Follman D, Hematti P, Sellers S, Laukkanen MO, Seggewiss R et al. The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood. 2004 Sep 1;104(5):1273-1280. https://doi.org/10.1182/blood-2003-08-2935
Kuramoto, Ken ; Follman, Dean ; Hematti, Peiman ; Sellers, Stephanie ; Laukkanen, Mikko O. ; Seggewiss, Ruth ; Metzger, Mark E. ; Krouse, Allen ; Donahue, Robert E. ; Von Kalle, Christof ; Dunbar, Cynthia E. / The impact of low-dose busulfan on clonal dynamics in nonhuman primates. In: Blood. 2004 ; Vol. 104, No. 5. pp. 1273-1280.
@article{9fbdcf935d3c4f20bfbef295bb0f4ce7,
title = "The impact of low-dose busulfan on clonal dynamics in nonhuman primates",
abstract = "An understanding of the number and contribution of individual pluripotent hematopoietic stem cells (HSCs) to the formation of blood lineages has important clinical implications for gene therapy and stem cell transplantation. We have been able to efficiently mark rhesus macaque long-term repopulating stem and progenitor cells with retroviral vectors, and track their in vivo contributions to hematopoiesis using the linear amplification mediated-polymerase chain reaction (LAM-PCR) technique of insertion site analysis. We assessed the impact of busulfan on contributions of individual retrovirally marked clones to hematopoiesis. There were 2 macaques that received transplants of retrovirally transduced CD34+ cells 2 years previously that were then treated with 4 mg/kg busulfan. Despite only transient and mild suppression of peripheral blood counts, the numbers of individual stem/progenitor clones contributing to granulocyte production decreased dramatically, by 80{\%} in the first monkey and by 60{\%} in the second monkey. A similar impact was seen on clones contributing to T cells. The clone numbers recovered gradually back toward baseline by 5 months following busulfan in the first monkey and by 3 months in the second monkey, and have remained stable for more than one year in both animals. Tracking of individual clones with insertionsite-specific primers suggested that clones contributing to hematopoiesis prior to busulfan accounted for the majority of this recovery, but that some previously undetected clones began to contribute during this recovery phase. These results indicate that even low-dose busulfan significantly affects stem and progenitor cell dynamics. The clonal diversity of hematopoiesis was significantly decreased after even a single, clinically well-tolerated dose of busulfan, with slow but almost complete recovery over the next several months, suggesting that true long-term repopulating stem cells were not permanently deleted. However, the prolonged period of suppression of many clones suggests that transplanted HSCs may have a marked competitive advantage if they can engraft and proliferate during this time period, and supports the use of this agent in nonmyeloablative regimens.",
author = "Ken Kuramoto and Dean Follman and Peiman Hematti and Stephanie Sellers and Laukkanen, {Mikko O.} and Ruth Seggewiss and Metzger, {Mark E.} and Allen Krouse and Donahue, {Robert E.} and {Von Kalle}, Christof and Dunbar, {Cynthia E.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1182/blood-2003-08-2935",
language = "English",
volume = "104",
pages = "1273--1280",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - The impact of low-dose busulfan on clonal dynamics in nonhuman primates

AU - Kuramoto, Ken

AU - Follman, Dean

AU - Hematti, Peiman

AU - Sellers, Stephanie

AU - Laukkanen, Mikko O.

AU - Seggewiss, Ruth

AU - Metzger, Mark E.

AU - Krouse, Allen

AU - Donahue, Robert E.

AU - Von Kalle, Christof

AU - Dunbar, Cynthia E.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - An understanding of the number and contribution of individual pluripotent hematopoietic stem cells (HSCs) to the formation of blood lineages has important clinical implications for gene therapy and stem cell transplantation. We have been able to efficiently mark rhesus macaque long-term repopulating stem and progenitor cells with retroviral vectors, and track their in vivo contributions to hematopoiesis using the linear amplification mediated-polymerase chain reaction (LAM-PCR) technique of insertion site analysis. We assessed the impact of busulfan on contributions of individual retrovirally marked clones to hematopoiesis. There were 2 macaques that received transplants of retrovirally transduced CD34+ cells 2 years previously that were then treated with 4 mg/kg busulfan. Despite only transient and mild suppression of peripheral blood counts, the numbers of individual stem/progenitor clones contributing to granulocyte production decreased dramatically, by 80% in the first monkey and by 60% in the second monkey. A similar impact was seen on clones contributing to T cells. The clone numbers recovered gradually back toward baseline by 5 months following busulfan in the first monkey and by 3 months in the second monkey, and have remained stable for more than one year in both animals. Tracking of individual clones with insertionsite-specific primers suggested that clones contributing to hematopoiesis prior to busulfan accounted for the majority of this recovery, but that some previously undetected clones began to contribute during this recovery phase. These results indicate that even low-dose busulfan significantly affects stem and progenitor cell dynamics. The clonal diversity of hematopoiesis was significantly decreased after even a single, clinically well-tolerated dose of busulfan, with slow but almost complete recovery over the next several months, suggesting that true long-term repopulating stem cells were not permanently deleted. However, the prolonged period of suppression of many clones suggests that transplanted HSCs may have a marked competitive advantage if they can engraft and proliferate during this time period, and supports the use of this agent in nonmyeloablative regimens.

AB - An understanding of the number and contribution of individual pluripotent hematopoietic stem cells (HSCs) to the formation of blood lineages has important clinical implications for gene therapy and stem cell transplantation. We have been able to efficiently mark rhesus macaque long-term repopulating stem and progenitor cells with retroviral vectors, and track their in vivo contributions to hematopoiesis using the linear amplification mediated-polymerase chain reaction (LAM-PCR) technique of insertion site analysis. We assessed the impact of busulfan on contributions of individual retrovirally marked clones to hematopoiesis. There were 2 macaques that received transplants of retrovirally transduced CD34+ cells 2 years previously that were then treated with 4 mg/kg busulfan. Despite only transient and mild suppression of peripheral blood counts, the numbers of individual stem/progenitor clones contributing to granulocyte production decreased dramatically, by 80% in the first monkey and by 60% in the second monkey. A similar impact was seen on clones contributing to T cells. The clone numbers recovered gradually back toward baseline by 5 months following busulfan in the first monkey and by 3 months in the second monkey, and have remained stable for more than one year in both animals. Tracking of individual clones with insertionsite-specific primers suggested that clones contributing to hematopoiesis prior to busulfan accounted for the majority of this recovery, but that some previously undetected clones began to contribute during this recovery phase. These results indicate that even low-dose busulfan significantly affects stem and progenitor cell dynamics. The clonal diversity of hematopoiesis was significantly decreased after even a single, clinically well-tolerated dose of busulfan, with slow but almost complete recovery over the next several months, suggesting that true long-term repopulating stem cells were not permanently deleted. However, the prolonged period of suppression of many clones suggests that transplanted HSCs may have a marked competitive advantage if they can engraft and proliferate during this time period, and supports the use of this agent in nonmyeloablative regimens.

UR - http://www.scopus.com/inward/record.url?scp=4444302256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444302256&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-08-2935

DO - 10.1182/blood-2003-08-2935

M3 - Article

VL - 104

SP - 1273

EP - 1280

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -